The current recruitment target is 640 patients. This target is amended throughout the course of the trial with the addition of more treatment arms and cohorts and removal of arms and cohorts showing insufficient signal of activity.
The exact size of each cohort may vary depending on the nature of the compound (cytostatic versus cytotoxic) and the required level of activity but will generally be of approximately 30 patients in order to generate the required signal of activity.
The following hospitals are open to recruitment to the National Lung Matrix Trial:
Royal Devon and Exeter Hospital
The following hospitals are closed to recruitment:
The following hospitals are planned or in set-up:
The following hospitals are open as National Lung Matrix Trial feeder hospitals, meaning they can consent patients to repeat National Lung Matrix Trial Molecular Testing Biopsies if the patient’s first biopsy did not provide a successful SMP2 result: